Asian Pacific Journal of Cancer Prevention

  • 제17권10호
  • /
  • Pages.4677-4680
  • /
  • 2016
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma

  • Machida, Yuichiro (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Sagawa, Motoyasu (Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University) ;
  • Tanaka, Makoto (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Motono, Nozomu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Matsui, Takuma (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Usuda, Katsuo (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Uramoto, Hidetaka (Department of Thoracic Surgery, Kanazawa Medical University)
  • 발행 : 2016.10.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The Glasgow Prognostic Score (GPS) is calculated from measured CRP and albumin levels. We here evaluated the significance of the GPS in patients with resected pulmonary adenocarcinoma. Materials and Methods: The present study included 156 patients with lung adenocarcinoma who underwent lobectomy at Kanazawa Medical University between 2002 and 2012. Classification was into three groups: those with normal albumin (>=3.5 g/dl) and C-reactive protein (CRP) (<=1.0 mg/dl) levels were classified as GPS 0 (n =136), those with low albumin (<3.5 g/dl) or elevated CRP (>1.0 mg/dl) levels as GPS 1 (n = 16), and those with low albumin (<3.5 g/dl) and elevated CRP (>1.0 mg/dl) levels as GPS 2 (n = 4). We retrospectively investigated relationships between the patient characteristics including the GPS, and disease-free survival and cancer-specific survival. Results: The pathological stages of the patients were as follows: IA (n=78, 50%), IB (n=31, 19.9%), IIA (n=20.0, 12.8%), IIB (n=9.0, 5.7%), and IIIA (n=18.0, 11.5%). Lobectomy was performed in all cases. The average GPS was 0.15 (0-2) and showed significant relationships with stage and tumor size. The 2-year survival rates in patients with GPS0, 1 and 2 were 81.4%, 38.4%, and 25.0%, respectively. Clear correlations were noted with both cancer-specific survival and disease-free survival. Furthermore, multivariate analysis revealed that GPS was a significant prognostic factor. Conclusions: The GPS could be a prognostic factor for patients with resected pulmonary adenocarcinoma.

키워드

참고문헌

  1. Al Murri AM, Bartlett JM, Canney PA, et al (2006). Evaluation of an inflammation-based prognostic score in patients with metastaic breast cancer. Br J Cancer, 94, 227-30. https://doi.org/10.1038/sj.bjc.6602922
  2. Canna K, Hilmy M, McMillan DC, et al (2008). The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Colorectal Dis, 10, 663-7. https://doi.org/10.1111/j.1463-1318.2007.01416.x
  3. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7. https://doi.org/10.1038/nature01322
  4. Crumley AB, Stuart RC, McKernan M, et al (2008). Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol, 23, 325-9. https://doi.org/10.1111/j.1440-1746.2007.05105.x
  5. Forrest LM, McMillan DC McArdle CS, et al (2003). Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J cancer, 89, 1028-30. https://doi.org/10.1038/sj.bjc.6601242
  6. Forrest LM, McMillan DC McArdle CS, et al (2005). A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer, 92, 1834-6. https://doi.org/10.1038/sj.bjc.6602591
  7. Goldstraw P, Crowley J, Chansky K, et al (2007). The IASLC lung cancer staging project: proposals for revison of the TNM stage grouping in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol, 2, 706-14. https://doi.org/10.1097/JTO.0b013e31812f3c1a
  8. Horino K, Beppu T, Kuroki H, et al (2013). Glasgow Prognostic Score as a prognostic factor for hepatectomy for hepatocellular. Int J Cli Oncol, 18, 829-38. https://doi.org/10.1007/s10147-012-0451-3
  9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  10. Jiang AG, Chen HL, Lu HY (2015). The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer. BMC cancer, 15, 386. https://doi.org/10.1186/s12885-015-1403-x
  11. Kawabata R, Imamura H, Kishimoto T, et al (2011). Second-line combination chemotherapy with docetaxel and nedaplatin for metastatic or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus cisplatin. Esophagus, 8, 179-85. https://doi.org/10.1007/s10388-011-0277-5
  12. La Torre M, Nigri G, Cavallini M, et al (2012). The Glasgow Prognostic Score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Sur Oncol, 19, 2917-23. https://doi.org/10.1245/s10434-012-2348-9
  13. Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 35, 2129-39.
  14. Mei Z, Liu Y, Liu C, et al (2014). Tumor-infiltrating inflammation and prognosis in colorectal acncer. Br J Cancer, 110, 1595-605. https://doi.org/10.1038/bjc.2014.46
  15. Mimatsu K, Oida T, Fukino N, et al (2014). GPS is a useful predictive factor of outcome after palliative gastrectomy for stage IV gastric cancer. AntiCaner Res, 34, 3131-6.
  16. Miyazaki T, Yamasaki N, Tsuchiya T, et al (2015). Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur J Cardiothorac Surg, 47, 140-5. https://doi.org/10.1093/ejcts/ezu514
  17. Petrella F, Radice D, Casiraghi M, et al (2016). Glasgow prognostic score class 2 predicts prolonged Intensive Care Unit Stay In Patients Undergoing Pneumonectomy. Ann Thorac Surg, 16, 30667-1.
  18. Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
  19. Tauler J, Mulshine JL (2009). Lung cancer and inflammation: interaction of chemokines and hnRNPs. Curr Opin Pharmacol, 9, 384-8. https://doi.org/10.1016/j.coph.2009.06.004
  20. Tomita M, Ayabe T, Chosa E, et al (2014). Prognostic significance of pre and postoperative glasgow prognostic score for patients with NSCLC. Anticancer Res, 34, 3137-40.
  21. Vashist YK, Loos J, Dedow J, et al (2011). Glasgow prognostic score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Sur Oncol, 18, 1130-8. https://doi.org/10.1245/s10434-010-1383-7